Life Sciences Cancer Immunotherapy Therapeutics sector
Strategic acquirers, private equity (buyout funds and growth funds) firms, and valuation benchmarks for Life Sciences Cancer Immunotherapy Therapeutics
1.1 - About Life Sciences Cancer Immunotherapy Therapeutics sector
Companies in Life Sciences Cancer Immunotherapy Therapeutics discover, engineer, and advance immune-based oncology treatments, spanning cell therapies, antibodies, ADCs, DNA medicines, and targeted inhibitors. They combine discovery platforms with clinical development and manufacturing to deliver precise tumor killing and durable responses, often addressing refractory cancers. Their value lies in translating immunobiology into approved and investigational therapies, improving patient survival while enabling partners to scale and commercialize cutting-edge modalities.
Typical capabilities include autologous and allogeneic CAR‑T design, antibody and antibody‑drug conjugate generation, and targeted small‑molecule programs such as gamma‑secretase or Notch pathway inhibition. Vendors deploy gene‑editing platforms like TALEN, DNA medicines and DNA‑encoded monoclonal antibodies, and functional genomics with pharmacodynamics profiling for target validation. Many offer decentralized cell therapy manufacturing, biomarker‑driven clinical development, and CMC processes to improve scalability, quality, and time‑to‑clinic.
Primary customers include biopharma companies pursuing co‑development or licensing, hospital oncology centers delivering advanced treatments, and academic research institutions running translational studies. These providers drive outcomes such as expanded pipelines in immuno‑oncology, faster trial activation and regulatory progress, improved response rates and durability in hard‑to‑treat tumors, and broader patient access through streamlined, near‑patient manufacturing and supply chains.
2. Buyers in the Life Sciences Cancer Immunotherapy Therapeutics sector
2.1 Top strategic acquirers of Life Sciences Cancer Immunotherapy Therapeutics companies
Incyte
- Description: Provider of prescription biopharmaceutical research, development and manufacturing services, delivering marketed and co-marketed medicines across oncology, inflammation and autoimmune diseases, and running manufacturing and R&D sites in North America, Europe and Asia from its Wilmington, Delaware headquarters.
- Key Products:
- Targeted Therapy Discovery: identifies therapeutic intervention points within interdependent tumor-growth pathways, leveraging cross-program knowledge to generate small-molecule candidates that may improve cancer outcomes
- Immunotherapy Discovery: uses functional genomics, pharmacodynamics and advanced bioinformatics to design monoclonal and bispecific antibodies that activate innate and adaptive immunity against tumors
- Jakafi (ruxolitinib) tablets: approved oral small-molecule therapy provided in multiple tablet strengths, giving patients a new treatment option as part of Incyte’s oncology portfolio
- IncyteCARES Patient Support Program: U.S. access, reimbursement, education and assistance service for eligible patients prescribed Jakafi
- Pemazyre or Opzelura, helping them understand insurance, obtain financial aid and receive ongoing support.
- Rationale: Provider of Targeted Therapy Discovery small-molecule platform, Immunotherapy Discovery monoclonal/bispecific antibody design, and Jakafi ruxolitinib oral JAK inhibitor, advancing immune-oncology.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
2.2 - Strategic buyer groups for Life Sciences Cancer Immunotherapy Therapeutics sector
M&A buyer group 1: Immunotherapy
Precigen
- Type: N/A
- Employees: ●●●●●
- Description: Provider of biotechnology solutions focused on human gene therapy and gene editing, leveraging proprietary DNA-engineering technologies to control cellular functions and develop treatments such as CAR-T therapies for acute myeloid leukemia.
- Key Products:
- PRGN-3006 CAR-T Therapy: Investigational CAR-T treatment granted orphan drug status targeting acute myeloid leukemia by genetically engineering patient T-cells to attack cancer cells and potentially improve clinical outcomes
- Proprietary DNA Engineering Platform: Suite of complementary technologies that enables precise DNA-based control over cellular functions, supporting creation of diverse gene and cell therapies
- Human Gene Editing Programs: Focused research initiatives applying advanced gene-editing techniques to develop next-generation therapeutics for multiple diseases using Precigen’s engineered cell and gene platforms
Buyer group 2: ████████ ████████
●● companiesBuyer group 3: ████████ ████████
●● companies3. Investors and private equity firms in Life Sciences Cancer Immunotherapy Therapeutics sector
3.1 - Buyout funds in the Life Sciences Cancer Immunotherapy Therapeutics sector
2.2 - Strategic buyer groups for Life Sciences Cancer Immunotherapy Therapeutics sector
4 - Top valuation comps for Life Sciences Cancer Immunotherapy Therapeutics companies
4.2 - Public trading comparable groups for Life Sciences Cancer Immunotherapy Therapeutics sector
Valuation benchmark group 1: Cell and Gene Therapy Biopharma Companies
Novartis
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of innovative medicines and treatments, focusing on the research, development, manufacturing, and marketing of patented pharmaceuticals in areas such as oncology, immunology, cardiovascular, ophthalmology, and neuroscience to improve and extend lives worldwide.
- Key Products:
- Oncology Treatments: Medications for various types of cancer
- Immunology Drugs: Treatments for autoimmune and inflammatory diseases
- Cardiovascular Medicines: Drugs for heart and vascular conditions
- Neuroscience Therapies: Pharmaceuticals for neurological and psychiatric disorders
- Ophthalmology Solutions: Treatments for eye diseases and conditions